Skip to main content
. 2018 Sep 19;10:96. doi: 10.1186/s13195-018-0424-5

Fig. 5.

Fig. 5

ADAS-Cog12. Change from baseline of ADAS-Cog12 score in patients with mild-to-moderate AD (a,c) or mild AD (b,d) in both the low-dose SC (a,b) and the high-dose IV (c,d) cohort. % Red percentage reduction, AD Alzheimer’s disease, ADAS-Cog12 12-point Alzheimer’s Disease Assessment Scale cognitive subscale, BL baseline, Cr crenezumab, Diff difference, IV intravenous, MMSE Mini-Mental State Examination, Pl placebo, SC subcutaneous, SE standard error